Sanofi Ventures has announced a substantial $625 million capital raise, bringing its total assets under management to approximately $1.4 billion. This infusion is targeted at accelerating breakthrough startups developing novel therapeutics across autoimmune diseases, neurological disorders, oncology, and other areas. The increased fund size positions Sanofi to enhance its strategic investments in biotechnology innovation at the venture level, underscoring big pharma’s growing role in early-stage biotech financing.